This section describes how to configure the localization process.
This section contains general information about working with the configuration of the IXIASOFT CCMS.
This section describes how to customize the Darwin Information Typing Architecture (DITA) standard functionalities of the CCMS.
This sections contains information and instructions for configuring roles, users, and access rights.
There are two localization models: the sequential localization model and the concurrent localization model.
The linguistic review process removes the translate="no" attribute from auto-translated text when preparing the localization kit.
translate="no"
The locidclasses.xml file in the system configuration enables you to determine to which elements the IXIASOFT CCMS adds the ixia_locid attribute when a topic is released or moves from one specified state to another, as configured in your system configuration.
ixia_locid
This sections describes how to configuring the IXIASOFT CCMS for the IXIASOFT Dynamic Release Management module.
You can optionally configure how track changes work inside IXIASOFT CCMS, whether email notifications are sent, and customizations of the IXIASOFT framework.
The Administration role within IXIASOFT CCMS Web enables a user with administrator privileges to access additional functions, including the ability to refresh the server for users, provide templates, adjust Collaborative Review settings, and more.
This page is available to Administrators within IXIASOFT CCMS Web, and they can use it to change settings relating to the approvals mechanism that conform to the FDA 21 CFR standard.
Administrators can create topic and map templates for the users of IXIASOFT CCMS Web. This enables administrators to structure the type of information that writers and SMEs can add to the CCMS Web.
The Repository contains your DITA content, images, resources, snapshots, taxonomies, DTDs, and system configuration.
This section provides troubleshooting information.
IXIASOFT Customer Support staff are available to answer your questions. We welcome your comments.
